Intervention
Iclepertin
ClinicalTrials.gov intervention label
How to interpret these research links
Connected source recordsThis is the original ClinicalTrials.gov intervention label, found in 4 distinct published trials. Registry interventions may represent drugs, devices, procedures or other study activities. A matched term or study association does not establish product equivalence, efficacy or regulatory approval.
Data basis: current published ClinicalTrials.gov records and, where present, RxNorm, MONDO and FDA-label identifiers. See the evidence interpretation and counting methodology.
Advertisement
Clinical trials
4 shownA Study to Test Long-term Safety of Iclepertin in People With Schizophrenia Who Took Part in a Previous CONNEX StudyNCT05211947 · 2022-03-21
TERMINATEDClinical Trial of Iclepertin Effect on Cognition and Functional Capacity in Schizophrenia (CONNEX-1)NCT04846868 · 2021-09-08
COMPLETEDClinical Trial of Iclepertin Effect on Cognition and Functional Capacity in Schizophrenia (CONNEX-2)NCT04846881 · 2021-08-24
COMPLETEDCONNEX-3: A Study to Test Whether Iclepertin Improves Learning and Memory in People With SchizophreniaNCT04860830 · 2021-08-09
COMPLETEDCommon conditions
Leading sponsors
Trial status mix
COMPLETED3
TERMINATED1
Phase mix
PHASE34
Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.